Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab- biosimilar) at ESMO 2020
Shots:
- The exploratory analyses of the P-III study evaluate the equivalent efficacy of Aybintio vs reference bevacizumab in combination with paclitaxel & carboplatin- q3w up to 6 cycles followed by Aybintio or reference bevacizumab as maintenance monothx. in 665 patients with metastatic/recurrent nsq. NSCLC
- Results: previous analysis demonstrate ORR in PPS (50.1% vs 44.8%); expanded analysis showed the risk difference in best ORR by 11 & 17wks. (2.2% vs 2.4%); mean of maximum % change from baseline in tumor burden @24wks. (-27.8% vs -27.3%)
- Aybintio is a biosimilar referencing Avastin and has received EC’s approval in Aug’2020 for mCRC- mBC- NSCLC- mRCC- epithelial ovarian- fallopian tube- primary peritoneal cancer and cervical cancer
Ref: The Investor | Image: Samsung Bioepis
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com